LOS ANGELES--(BUSINESS WIRE)--
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC)
announced that the US Patent and Trademark Office (USPTO) has issued a
patent covering methods of use of interleukin 13-receptor alpha 2
protein (IL-13Rα2) in cancer immunotherapy. IL-13 is an immune
regulatory cytokine and IL-13Rα2 is highly and specifically expressed in
glioblastoma, ovarian and other solid tumors, but not in normal tissue.
IL-13Rα2 is an important target of ImmunoCellular's lead product
candidate, ICT-107, a dendritic cell vaccine directed against
glioblastoma antigens and cancer stem cells, as well as ICT-140, a
dendritic cell vaccine to treat ovarian cancer.
"We believe that this issued patent will complement and extend the broad
intellectual property protection we have established for two of our
company's key assets, ICT-107 and ICT-140, and represents a valuable
addition to our patent estate," said Andrew Gengos, ImmunoCellular Chief
Executive Officer. "IL-13Rα2 is a tumor-associated antigen present in
the majority of brain cancers, and we believe that using an
immunotherapeutic vaccine that targets this and other specific antigens
as well as cancer stem cells to stimulate an immune response represents
a promising anticancer approach."
The IL-13Rα2 patent was issued to The Penn State Research Foundation,
the technology transfer agent for The Pennsylvania State University, and
is licensed to Targepeutics, Inc.ImmunoCellular is a sub-licensee of
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular is conducting a phase II trial
of its lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting
ovarian cancer antigens and cancer stem cells. To learn more about
ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular
This press release contains certain forward-looking statements that are
subject to a number of risks and uncertainties, including the risk that
ICT-107 can be further successfully developed or commercialized.
Additional risks and uncertainties are described in IMUC's most recently
filed quarterly report on Form 10-Q and annual report on Form 10-K.
Except as permitted by law, IMUC undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
Source: ImmunoCellular Therapeutics, Ltd.
News Provided by Acquire Media